We are focused on developing non-invasive prenatal diagnostic tests based on fetal DNA present in maternal blood. As early as 5 weeks gestation, testing involves a blood sample from pregnant mother, swab sample from alleged father.
Ravgen’s technology allows for non-invasive prenatal genetic testing for single gene disorders and chromosomal abnormalities, such as CF, SMA, and sickle cell anemia. Feel free to contact us about specific disorder testing.
Ravgen’s core technology is based on its ability to increase the percentage of fetal DNA that is found in the mother’s blood. Through its research with free floating fetal DNA, the company has developed and patented a variety of noninvasive prenatal tests that simply require a safe blood draw from the mother.
Ravgen’s work has been published in widely recognized and internationally accepted, peer reviewed journals. View our publications on noninvasive fetal DNA testing by clicking on the images to the right. Ravgen has been published in many medical publications such as: The New England Journal of Medicine, The Lancet and The Journal of the American Medical Association.
You can also visit the news page to see other publications that Ravgen has been published in.
WEB
WEB
Dr. Dhallan has extensive and diverse training in biomedical engineering, clinical research, and medicine, and has published numerous articles on genetic research in widely recognized and internationally accepted peer-reviewed journals. Dr. Dhallan has not only provided leadership for Ravgen’s business strategy but is also the inventor of Ravgen’s proprietary technology. Prior to founding Ravgen in September of 2000, Dr. Dhallan was a residency-trained, board-certified emergency room physician. Dr. Dhallan earned his M.D. and Ph.D. from The Johns Hopkins University School of Medicine in Baltimore, Maryland, and his MBA from The Wharton School of Business at the University of Pennsylvania.
